Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage AI company raised $365M Series D at $1.6B for world's largest multimodal oncology AI; Novo Nordisk partnership; $467M total; combines pathology imaging, genomics, and clinical records to predict treatment responses and guide precision cancer care.
Pathos AI is a clinical-stage AI company building the world's largest multimodal oncology AI platform, combining pathology imaging, genomics, clinical records, and treatment outcome data to power precision cancer care. Founded by oncologists, pathologists, and AI researchers, Pathos has assembled a dataset at a scale that gives its models a meaningful edge: by ingesting vast quantities of multimodal cancer data, its platform can predict treatment responses, identify biomarkers, and guide therapy selection with a level of accuracy that single-modality systems cannot match.\n\nThe platform serves oncologists and cancer centers by providing AI-augmented pathology reads, treatment outcome predictions, and clinical trial matching. Pathos's AI can analyze whole-slide pathology images in combination with molecular and clinical data to generate insights that inform diagnosis and treatment decisions. The company has also built partnerships with pharmaceutical companies — including Novo Nordisk and Prelude Therapeutics — to use its platform for drug development and clinical trial design, adding a biopharma revenue stream alongside its clinical business.\n\nPathos raised $365M in a Series D round at a $1.6B valuation, bringing total funding to $467M. The Series D was one of the largest oncology AI fundraises in history and included backing from top-tier life sciences investors. The Novo Nordisk and Prelude partnerships validate the platform's scientific depth and its utility across both clinical care and drug development. As of 2025–2026, Pathos is advancing toward direct clinical deployment and regulatory submissions, positioning itself as a core infrastructure layer for the future of AI-guided cancer treatment.
Oracle Corporation's healthcare IT division (rebranded Cerner, $28.3B acquisition 2022); #2 US hospital EHR, VA/DoD federal EHR program, OCI cloud migration + ambient clinical AI competing with Epic Systems.
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, revenue cycle management, and population health analytics to hospitals, health systems, physician practices, ambulatory clinics, and government health agencies globally — operating as the rebranded Cerner Corporation following Oracle's $28.3 billion acquisition of Cerner in June 2022, the largest acquisition in Oracle's history. Oracle Health's EHR platform (the Cerner Millennium clinical information system) powers clinical documentation, physician order entry, nursing workflows, medication administration, and patient care coordination for approximately 30% of US hospitals — making Oracle Health the second-largest EHR vendor in the US hospital market after Epic Systems. A major integration program is underway to migrate Cerner's clinical applications to Oracle Cloud Infrastructure (OCI), enabling Oracle Health to leverage Oracle's cloud scale, Oracle's AI capabilities (generative AI for clinical documentation, ambient listening for physician notes), and Oracle's database performance advantages for health record analytics. Oracle Corporation named Clay Magouyrk and Mike Sicilia as co-CEOs in 2025 (replacing Safra Catz), positioning Oracle Health's clinical platform to benefit from the next-generation Oracle leadership team's emphasis on cloud and AI transformation.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.